News & Conferences

VaxForm awarded Phase II STTR grant

Sep 5, 2013 10:04 am

Bethlehem, PA:  Following successful completion of Phase I investigations, VaxForm has been awarded a Phase II STTR grant to continue development of a vaccine targeting diseases resulting from Streptococcus pyogenes infection.  The company will receive $750,000 for work over the next two years to progress the development of the vaccine to phase I clinical trials. 

S. pyogenes, is a Gram-positive bacterium that causes a wide variety of diseases such as strep throat, scarlet fever, necrotizing fasciitis, streptococcal toxic shock syndrome, and impetigo. Asymptomatic infections and carriage are also common features of S.pyogenes infection.  Worldwide an estimated 500,000 deaths annually are attributed to S.pyogenes infection. An effective vaccine could save thousands of lives and allow for billions of dollars in medical cost savings by reducing the rate of disease in the population. 

            The vaccine incorporates a recombinant protein fusion between Streptococcal pyrogenic exotoxin B (SpeB), and Streptococcal pyrogenic exotoxin A (SpeA).  Using VaxForm’s expertise and development strategy, a safe and effective vaccine can be rapidly developed to reduce the morbidity and mortality burden of disease as well as cost of medical treatment in both military and civilian populations.